EWEdwards Lifesciences

$90.77

$72.6552 weeks$93.68

Price

$90.77+15%1Y

1M+8.4%1Y+15%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average

7/10

Value30

Quality85

Momentum57

Growth65

Strongest Quality, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence, and meaningful partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Edwards Lifesciences has been a leader in our field for over six decades.

In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR

P/E (TTM)52.2

Market Cap$50.30B

1Y Return+15%

5Y Return-19%

Business segments

Q1 2026 · $1.65B

The company’s own SEC segment disclosure.

Transcatheter Aortic Valve Replacement$1.20B73%
Surgical$276.2M17%
Transcatheter Mitral And Tricuspid Therapies$175.1M11%

Edwards Lifesciences (EW) reported revenue of $1.74B in Q2 2026 (quarter ended June 30, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $241M (14% of revenue). For the full year FY2025, revenue was $6.07B (+12% year on year) and net income $1.07B. Its largest product in 2026-Q1 was Transcatheter Aortic Valve Replacement at $1.20B, 73% of the disclosed total, just ahead of Surgical at 17%.

Raw charts

11 series · TTM

As reported to the SEC, without any scoring.

Medical Devices

Ranks #18 of 35 by Smart Score